German committee recommends against reimbursement for Avandia and Actos

An influential Germany group has recommended that health insurers stop paying for Avandia (rosiglitazone, GlaxoSmithKline) and Actos (pioglitazone, Takeda). The recommendation was made by Germany’s Federal Joint Committee of doctors and health insurers. A Reuters news story quoted the committee chairman, Rainer Hess:  there are other pharmaceuticals that have no such side effects and long-term risks. We believe that patients should be protected against useless and, more importantly, harmful therapies.”


Speak Your Mind